This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): dexmethylphenidate hydrochloride, d-MPH
Description: Focalin (dexmethlyphenidate hydrochloride) contains only the effective d-isomer, and is a refined form of Ritalin (d,l-thero-methlyphenidate hydrochloride), which provides similar efficacy and a favorable side effect profile at half the Ritalin milligram dosage. It exerts its effects by blocking the reuptake of dopamine and norepinephrine.
Deal Structure: Celgene entered into an agreement with Novartis in April 2000 in which the company granted to Novartis an exclusive license (excluding Canada) for the developmentand marketing of Focalin. Celgene received a $10 million upfront payment in July 2000, a $5 million milestone payment in December 2000 and a $12.5 million milestone payment in November 2001. Celgene is currently selling Focalin to Novartis as well as receiving royalties on all of Novartis' Ritalin family of ADD- and ADHD-related products.
Celegene has retained the exclusive commercial rights to Focalin and Focalin XR for oncology-related disorders, such as chronic fatigue associated with chemotherapy.
Partners: Johnson Matthey Plc Celgene Corporation
Pink Sheet Novartis Focalin ADHD approval
Additional information available to subscribers only: